Periodontitis pipeline therapeutics constitutes close to 15 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities Institutes.
Periodontitis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Periodontitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Periodontitis Periodontitis is a gum infection that damages the soft tissue and destroys the bone that supports teeth. Signs and symptoms of periodontitis include swollen gums, bright red or purplish gums, bad breath, bright red or purplish gums and spaces developing between teeth. Risk factors include gingivitis, heredity, diabetes, age, substance abuse and weakened immune system.
The molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects.
Key Topics Covered:
- Periodontitis Overview
- Therapeutics Development
- Pipeline Products for Periodontitis - Overview
- Pipeline Products for Periodontitis - Comparative Analysis
- Periodontitis - Therapeutics under Development by Companies
- Periodontitis - Therapeutics under Investigation by Universities/Institutes
- Periodontitis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Periodontitis - Products under Development by Companies
- Periodontitis - Products under Investigation by Universities/Institutes
- Periodontitis - Companies Involved in Therapeutics Development
- Amyndas Pharmaceuticals LLC
- C3 Jian, Inc
- CSL Limited
- Ensol Biosciences Inc.
- Enzo Biochem, Inc.
- Geistlich Pharma AG
- Kaken Pharmaceutical Co., Ltd.
For more information about this report visit http://www.researchandmarkets.com/research/j68dd5/periodontitis